HK1172346A1 - Peptide vaccines for cancers expressing tumor-associated antigens - Google Patents

Peptide vaccines for cancers expressing tumor-associated antigens

Info

Publication number
HK1172346A1
HK1172346A1 HK12112989A HK12112989A HK1172346A1 HK 1172346 A1 HK1172346 A1 HK 1172346A1 HK 12112989 A HK12112989 A HK 12112989A HK 12112989 A HK12112989 A HK 12112989A HK 1172346 A1 HK1172346 A1 HK 1172346A1
Authority
HK
Hong Kong
Prior art keywords
associated antigens
expressing tumor
peptide vaccines
cancers expressing
cancers
Prior art date
Application number
HK12112989A
Other languages
English (en)
Chinese (zh)
Inventor
Takuya Tsunoda
Ryuji Ohsawa
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of HK1172346A1 publication Critical patent/HK1172346A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46443—Growth factors
    • A61K39/464434—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
HK12112989A 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens HK1172346A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21

Publications (1)

Publication Number Publication Date
HK1172346A1 true HK1172346A1 (en) 2013-04-19

Family

ID=39709837

Family Applications (7)

Application Number Title Priority Date Filing Date
HK10102517.8A HK1134507A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112987.6A HK1172344A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112988.5A HK1172345A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing hig2 tumor-associated antigens hig2
HK12112897.5A HK1172041A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112898.4A HK1172042A1 (zh) 2007-02-21 2010-03-10 用於表達腫瘤相關抗原的癌症的肽疫苗
HK12112989A HK1172346A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112899.3A HK1172043A1 (en) 2007-02-21 2010-03-10 Epha4 derived peptide vaccines epha4

Family Applications Before (5)

Application Number Title Priority Date Filing Date
HK10102517.8A HK1134507A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112987.6A HK1172344A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112988.5A HK1172345A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing hig2 tumor-associated antigens hig2
HK12112897.5A HK1172041A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112898.4A HK1172042A1 (zh) 2007-02-21 2010-03-10 用於表達腫瘤相關抗原的癌症的肽疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12112899.3A HK1172043A1 (en) 2007-02-21 2010-03-10 Epha4 derived peptide vaccines epha4

Country Status (28)

Country Link
EP (20) EP2476695A3 (ko)
JP (6) JP5239103B2 (ko)
KR (8) KR101644877B1 (ko)
CN (4) CN104292299B (ko)
AR (1) AR068302A1 (ko)
AU (1) AU2008218463B2 (ko)
BR (1) BRPI0808421B1 (ko)
CA (3) CA2678755C (ko)
CO (1) CO6190536A2 (ko)
CY (2) CY1114590T1 (ko)
DK (3) DK2465864T3 (ko)
ES (6) ES2530777T3 (ko)
HK (7) HK1134507A1 (ko)
HR (3) HRP20131044T1 (ko)
IL (10) IL200478A (ko)
MX (4) MX337456B (ko)
MY (2) MY173379A (ko)
NZ (4) NZ591704A (ko)
PH (1) PH12014501642A1 (ko)
PL (3) PL2476694T3 (ko)
PT (2) PT2465864E (ko)
RU (1) RU2464275C2 (ko)
SG (3) SG179402A1 (ko)
SI (3) SI2465864T1 (ko)
TW (5) TWI610939B (ko)
UA (1) UA100372C2 (ko)
WO (1) WO2008102557A1 (ko)
ZA (1) ZA200905881B (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882698B (zh) 2003-08-20 2011-05-25 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
CN104356225B (zh) 2007-08-20 2018-02-13 肿瘤疗法科学股份有限公司 Cdh3 肽以及含有cdh3 肽的药剂
WO2010001585A1 (en) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
EP2362906B1 (en) * 2008-10-22 2015-04-08 Oncotherapy Science, Inc. Rab6kifl/kif20a epitope peptide and vaccines containing the same
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
BRPI0923402A2 (pt) * 2008-12-24 2015-08-04 Oncotherapy Science Inc Peptídeos c10rf59 e vacinas incluindo os mesmos.
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
ES2701626T3 (es) 2009-12-28 2019-02-25 Oncotherapy Science Inc Anticuerpos anti-CDH3 y sus usos
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
TW201627003A (zh) * 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
AU2011336019B2 (en) * 2010-12-02 2016-07-07 Oncotherapy Science, Inc. TOMM34 peptides and vaccines including the same
KR102355121B1 (ko) * 2011-12-14 2022-02-09 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 요법을 위한 병립 유전자 비활성화 생물표식과 표적들
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
JP6255594B2 (ja) * 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
EP2872530A4 (en) * 2012-07-10 2016-04-06 Oncotherapy Science Inc KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
JP5920742B2 (ja) * 2012-08-31 2016-05-18 ジーン・ステム株式会社 Ｐｓｆ１由来ペプチド
DK2895600T3 (da) 2012-09-11 2020-04-27 Onco Therapy Science Inc Ube2t-peptider og vacciner, der indeholder disse
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
AU2014288127A1 (en) * 2013-07-12 2016-02-18 Sapporo Medical University Tumor antigen peptide
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
BR112017002193A2 (pt) * 2014-08-04 2017-11-21 Oncotherapy Science Inc peptídeo derivado de urlc10 e vacina contendo o mesmo
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
BR112018070183A2 (pt) * 2016-03-31 2019-04-16 Neon Therapeutics, Inc. neoantígenos e métodos de seu uso
WO2018090257A1 (zh) * 2016-11-16 2018-05-24 深圳华大基因研究院 多肽及其应用
SI3573600T1 (sl) 2017-01-25 2022-07-29 Ose Immunotherapeutics Postopek za proizvodnjo obstojne emulzije za dostavo peptida
EP3601539A4 (en) * 2017-03-28 2021-01-13 Zhenglun Zhu METHODS OF TREATING NEOPLASIC DISEASES
KR102190890B1 (ko) * 2017-08-10 2020-12-15 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
MY182816A (en) * 2018-02-15 2021-02-05 National Univ Corporation Asahikawa Medical Univ Cancer antigen peptide
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995028484A1 (en) * 1994-04-15 1995-10-26 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
WO1997005900A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
AU6795898A (en) * 1997-04-04 1998-10-30 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1375515A3 (en) * 1997-10-07 2004-04-21 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same, and use thereof
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
WO2001029221A2 (en) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
AU2001278076A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-5 proteins and related reagents and methods of use thereof
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
US20040236091A1 (en) * 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
WO2002102235A2 (en) * 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2003217966A1 (en) * 2002-03-07 2003-10-08 Licentia, Ltd. Lymphatic and blood endothelial cell genes
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003300680A1 (en) * 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
JP2006517788A (ja) * 2002-12-20 2006-08-03 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １５９８６、２１８８、２０７４３、９１４８、９１５１、９７９１、４４２５２、１４１８４、４２４６１、８２０４、７９７０、２５５５２、２１６５７、２６４９２、２４１１、１５０８８、１９０５、２８８９９、６３３８０、３３９３５、１０４８０、１２６８６、２５５０１、１７６９４、１５７０１、５３０６２、４９９０８、２１６１２、３８９４９、６２１６、４６８６３、９２３５、２２０１、６９８５、９８８３、１２２３８、１８０５７、２１６１７、３９２２８、４９９２８、５４４７６、６２１１３、６４３１６、１２２６４、３２３６２、５８１９８、２８８７、３２０５、８５５７、９６００、９６９３、４４８６７、５３０５８、５５５５６、５７６５８、２２０８、１０２５２、１０３０２、１４２１８、３３８７７、１０３１７、１０４８５、２５９６４、１４８１５、１３６３、１３９７、１４８２７、２１７０８、３８０１、６４６９８、２１７９または１３２４９を使用する癌を処置するための方法および組成物
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
WO2005001138A2 (en) * 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN1882698B (zh) * 2003-08-20 2011-05-25 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
WO2005083086A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
EP1757306A4 (en) * 2004-04-09 2010-05-19 Genecare Res Inst Co Ltd AGENT INDUCING APOPTOSIS SPECIFIC TO CARCINOMA CELLS TARGETING A GENE INVOLVED IN STABILIZING CHROMOSOMES
CA2566506A1 (en) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
CA2598889A1 (en) * 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
ES2364670T3 (es) * 2005-02-25 2011-09-12 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk.
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
JP4803460B2 (ja) * 2005-08-09 2011-10-26 学校法人 久留米大学 Ｈｌａ−ａ２４分子結合性扁平上皮癌抗原由来ペプチド
CN103242428B (zh) * 2005-08-09 2015-04-15 肿瘤疗法.科学股份有限公司 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3 (gpc3)的癌症排斥抗原肽以及含有该肽的药物
KR101130597B1 (ko) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산
US20090263832A1 (en) * 2005-11-30 2009-10-22 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways
CN101467039B (zh) * 2006-04-10 2013-11-06 健泰科生物技术公司 散乱蛋白pdz调节剂
CA2655361C (en) * 2006-06-16 2014-10-07 Kumamoto University Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same
EP1972639A3 (en) * 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
CN104356225B (zh) * 2007-08-20 2018-02-13 肿瘤疗法科学股份有限公司 Cdh3 肽以及含有cdh3 肽的药剂
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
EP2483690A1 (de) * 2009-09-29 2012-08-08 Protagen AG Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung

Also Published As

Publication number Publication date
EP2594581A3 (en) 2013-08-14
EP2573110A2 (en) 2013-03-27
RU2009135020A (ru) 2011-03-27
HRP20131044T1 (hr) 2013-12-06
HK1172043A1 (en) 2013-04-12
CO6190536A2 (es) 2010-08-19
EP2570428A2 (en) 2013-03-20
TWI615403B (zh) 2018-02-21
IL219043A (en) 2014-12-31
EP2573110A3 (en) 2013-09-04
CA2678755C (en) 2016-04-26
EP2465865B1 (en) 2016-11-02
EP2476695A3 (en) 2012-12-12
ES2530777T3 (es) 2015-03-05
EP2567971A2 (en) 2013-03-13
TW201422637A (zh) 2014-06-16
JP2010519176A (ja) 2010-06-03
EP2476692A2 (en) 2012-07-18
JP5239104B2 (ja) 2013-07-17
EP2573109A2 (en) 2013-03-27
KR101644871B1 (ko) 2016-08-02
TW200844111A (en) 2008-11-16
CA2992074A1 (en) 2008-08-28
JP5874158B2 (ja) 2016-03-02
KR20150064236A (ko) 2015-06-10
EP2574623A3 (en) 2013-07-17
EP2476692A3 (en) 2012-12-19
EP2594582A2 (en) 2013-05-22
KR101543623B1 (ko) 2015-08-11
EP2476694A2 (en) 2012-07-18
AR068302A1 (es) 2009-11-11
ES2527397T3 (es) 2015-01-23
JP5614761B2 (ja) 2014-10-29
PL2465864T3 (pl) 2015-03-31
EP2465864A2 (en) 2012-06-20
EP2465865A2 (en) 2012-06-20
IL219044A (en) 2014-12-31
EP2121731A4 (en) 2010-04-21
MX337456B (es) 2016-03-03
ZA200905881B (en) 2010-05-26
EP2570429A2 (en) 2013-03-20
JP2013091645A (ja) 2013-05-16
DK2465864T3 (en) 2014-11-24
KR101511134B1 (ko) 2015-04-28
CN104292299B (zh) 2017-09-29
EP2465864A3 (en) 2012-10-03
IL200478A (en) 2015-11-30
EP2465865A3 (en) 2013-07-24
KR20140130507A (ko) 2014-11-10
ES2540893T3 (es) 2015-07-14
MY155029A (en) 2015-08-28
PH12014501642B1 (en) 2015-12-02
IL219042A (en) 2016-03-31
HK1172344A1 (en) 2013-04-19
TW201623325A (zh) 2016-07-01
IL219044A0 (en) 2012-05-31
KR20140121489A (ko) 2014-10-15
EP2476693A3 (en) 2012-10-03
CN103351423A (zh) 2013-10-16
ES2435194T3 (es) 2013-12-16
KR20090121349A (ko) 2009-11-25
AU2008218463B2 (en) 2013-01-17
EP2567971A3 (en) 2013-06-26
KR101644877B1 (ko) 2016-08-03
EP2565203A1 (en) 2013-03-06
AU2008218463A2 (en) 2009-11-26
CN102863514B (zh) 2014-12-10
KR20150116463A (ko) 2015-10-15
NZ602122A (en) 2014-03-28
EP2121731A1 (en) 2009-11-25
ES2541863T3 (es) 2015-07-27
HRP20141233T1 (hr) 2015-02-27
JP5608953B2 (ja) 2014-10-22
IL219040A0 (en) 2012-05-31
BRPI0808421B1 (pt) 2021-10-05
SI2465864T1 (sl) 2014-12-31
TWI596109B (zh) 2017-08-21
IL219048A (en) 2015-07-30
HK1172345A1 (en) 2013-04-19
IL219043A0 (en) 2012-05-31
HK1172041A1 (en) 2013-04-12
UA100372C2 (ru) 2012-12-25
EP2570430A3 (en) 2013-07-10
CA2678755A1 (en) 2008-08-28
CN102863514A (zh) 2013-01-09
NZ602119A (en) 2014-03-28
AU2008218463A1 (en) 2008-08-28
EP2476695A2 (en) 2012-07-18
IL200478A0 (en) 2010-04-29
EP2570430A2 (en) 2013-03-20
EP2583976A2 (en) 2013-04-24
JP5239103B2 (ja) 2013-07-17
EP2476693A2 (en) 2012-07-18
TW201433574A (zh) 2014-09-01
NZ579768A (en) 2012-03-30
JP2014210804A (ja) 2014-11-13
MY173379A (en) 2020-01-21
IL219047A0 (en) 2012-05-31
TWI610939B (zh) 2018-01-11
SG10201909675QA (en) 2019-11-28
EP2573109A3 (en) 2013-06-19
EP2476694A3 (en) 2013-04-24
PT2121731E (pt) 2013-10-24
EP2476694B1 (en) 2014-11-19
EP2570428A3 (en) 2013-07-10
IL219046A0 (en) 2012-05-31
CA2919248A1 (en) 2008-08-28
IL219041A (en) 2014-12-31
SI2121731T1 (sl) 2013-10-30
HK1134507A1 (en) 2010-04-30
KR20150018895A (ko) 2015-02-24
TW201538522A (zh) 2015-10-16
KR20130023407A (ko) 2013-03-07
EP2465866A3 (en) 2012-10-10
KR20160045939A (ko) 2016-04-27
SG179402A1 (en) 2012-04-27
EP2121731B1 (en) 2013-08-14
EP2465867A3 (en) 2012-10-10
CN101663315A (zh) 2010-03-03
CN103351423B (zh) 2016-09-28
JP2013116895A (ja) 2013-06-13
TWI494319B (zh) 2015-08-01
CY1114590T1 (el) 2016-10-05
NZ591704A (en) 2012-09-28
CN104292299A (zh) 2015-01-21
MX337417B (es) 2016-03-03
EP2594581A2 (en) 2013-05-22
KR101540000B1 (ko) 2015-07-29
DK2476694T3 (en) 2014-12-08
KR101511140B1 (ko) 2015-04-10
PL2476694T3 (pl) 2015-04-30
EP2570429A3 (en) 2013-08-28
CA2992074C (en) 2021-01-05
PH12014501642A1 (en) 2015-12-02
EP2574623A2 (en) 2013-04-03
JP2016094459A (ja) 2016-05-26
TWI438207B (zh) 2014-05-21
JP2010209060A (ja) 2010-09-24
IL219046A (en) 2015-02-26
EP2465867B1 (en) 2015-04-01
ES2532708T3 (es) 2015-03-31
WO2008102557A1 (en) 2008-08-28
DK2121731T3 (da) 2013-10-21
MX2009009022A (es) 2010-03-03
EP2476692B1 (en) 2015-04-15
CY1115841T1 (el) 2017-01-25
RU2464275C2 (ru) 2012-10-20
PT2465864E (pt) 2015-01-14
HK1172042A1 (zh) 2013-04-12
BRPI0808421A2 (pt) 2017-08-29
EP2465864B1 (en) 2014-10-08
IL219048A0 (en) 2012-05-31
IL219042A0 (en) 2012-05-31
CN101663315B (zh) 2014-10-15
EP2465866A2 (en) 2012-06-20
SI2476694T1 (sl) 2015-02-27
MX359680B (es) 2018-09-28
EP2476693B1 (en) 2014-12-24
EP2583976A3 (en) 2013-10-23
IL219040A (en) 2014-12-31
SG10201506589WA (en) 2015-09-29
IL219045A0 (en) 2012-05-31
HRP20150108T1 (hr) 2015-05-08
EP2465867A2 (en) 2012-06-20
IL219041A0 (en) 2012-05-31
EP2594582A3 (en) 2013-08-14
PL2121731T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
IL219044A0 (en) Peptide vaccines for cancers expressing tumor-associated antigens
IL228948A0 (en) Antibody against cancer antigen-helping peptide
HK1171024A1 (en) Peptide vaccines for cancers expressing mphosph1 polypeptides mphosph1
EP2006377A4 (en) NEW TUMORANT PEPTIDES
ZA200905874B (en) Monoclonal human tumor-specific antibody
ZA201001260B (en) Immunogenic polypeptides and monoclonal antibodies
EP2106442A4 (en) ANTIBODIES MODIFYING CANCER DISEASE
HK1142813A1 (en) Survivin peptides as cancer vaccines
EP2106441A4 (en) ANTIBODIES FOR THE MODIFICATION OF CANCER DISEASES
EP2104732A4 (en) ANTIBODIES FOR THE MODIFICATION OF CANCER DISEASES
EP2455102A4 (en) CANCER THERAPEUTIC AGENT COMPRISING AN ANTIBODY AGAINST CANCER SPECIFIC MEMBRANE ANTIGEN
GB0720156D0 (en) Breast cancer associated antigen
IL197737A0 (en) Antigen specific multi epitope vaccines
GB0716224D0 (en) Peptides for vaccine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230221